4DMedical (ASX:4DX) published peer-reviewed CT VQ data in AJRCCM showing lung surgery success rates lift from 46% to 76% via better patient selection.
Life Sciences
AVITA Medical (ASX:AVH) Q1 2026 revenue rose 10% sequentially to US$19.3m but cash fell to US$14.3m as a new CEO and BARDA deal reset the story.
It is hard to look back on something and say it failed especially if it was a US$11.7bn bet as CSL's Vifor acquisition was. But what else can you say? Impairments now total roughly US$6.5bn, the share price is barely over $100 having peaked at over $300 only a couple of years ago and the…
ImpediMed (ASX:IPD) raised A$15.2m and cut costs as it works toward FY28 operating cash flow breakeven through SOZO growth.
For every one of the ASX Biotech Success Stories, there are several failures. While a handful of companies can and do convert clinical data into extraordinary value, many others run into the barrier that decides everything: the primary endpoint.The successes tend to follow a recognisable pattern — a credible clinical signal, external validation, and either…
LTR Pharma (ASX:LTP) reported 10 minute SPONTAN Tmax data with no serious safety events, strengthening its planned FDA pathway.
Shares in Dimerix fell over 35% this morning and some may think the decline was irrational. After all, the announcement confirmed >90 per cent statistical power for its primary endpoint, reminded the market that its 2024 futility analysis showed the drug outperforming placebo, and reported no safety issues across seven IDMC reviews. On paper, that…
Percheron Therapeutics is not the kind of company that typically commands market attention at a A$6–7m valuation. Yet the more one looks at its trajectory over the past twelve months, the more it becomes clear that the market is missing something important. The company has moved from being a near‑dormant shell to a clinical‑stage immuno‑oncology…
The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their cash as they have earned on their investments. We felt that it was time to write a stand-alone article about this in light of the inflation crisis and how it could lead to investors seeking…
The imminent US Marijuana Rescheduling begs the question: Is it really different this time for ASX pot stocks? In one sense, perhaps it is, because it is undoubtedly the most significant policy signal in more than 50 years. But in the other, there's no promise it'll lead to anything, as recent history has shown.
What's Happening…
